Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes. [electronic resource]
Producer: 20210907Description: 868-875 p. digitalISSN:- 1464-5491
- Adamantane -- analogs & derivatives
- Aged
- Diabetes Complications -- epidemiology
- Diabetes Mellitus, Type 2 -- complications
- Dipeptides -- therapeutic use
- Dipeptidyl-Peptidase IV Inhibitors -- therapeutic use
- Exenatide -- therapeutic use
- Female
- Humans
- Hypoglycemic Agents -- therapeutic use
- Incidence
- Incretins -- therapeutic use
- Linagliptin -- therapeutic use
- Liraglutide -- therapeutic use
- Lung Neoplasms -- epidemiology
- Male
- Middle Aged
- Proportional Hazards Models
- Pulmonary Disease, Chronic Obstructive -- epidemiology
- Risk Factors
- Sitagliptin Phosphate -- therapeutic use
- Smoking -- epidemiology
- Glucagon-Like Peptide-1 Receptor Agonists
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.